Atrix to sell gel in Switzerland

Atrix Laboratories Inc. received approval in Switzerland to market Atridox using the Atrigel delivery system for periodontal disease. The product is already marketed in the United States, Canada, New Zealand, the United Kingdom and all of the 14 other European countries in the European Union. Atridox combines the company’s Atrigel drug delivery system with the antibiotic doxycycline to reduce bacteria associated with periodontal disease. The gel is applied to the affected periodontal pocket, where it solidifies, then releases the antibiotic over a week’s time.

Atrix, a Fort Collins-based pharmaceutical company, currently holds five patents for its drug delivery systems.